



RESEARCH SERVICES
Clinical Trials and Research Governance
Joint Research Office
Boundary Brook House
Churchill Drive
Headington, Oxford
OX3 7GB

To whom it may concern

Date: 13/03/2020

Dear Sir/Madam,

Title: Randomised Evaluation of COVID-19 Therapy (RECOVERY)

PID: 14892

Protocol Date/Version: 13-03-2020; V1.0.

The above Clinical Trial has been designed by Peter Horby and colleagues at the University of Oxford and funded by UK Research and Innovation. I confirm that the University will accept the role of Research Sponsor of this trial in accordance with the Medicines for Human Use (Clinical Trials) Regulations 2004 and Amendment 2006.

Insurance-provided indemnity arrangements are in place for the project:
Newline Underwriting Management Ltd., at Lloyd's of London.

Sponsorship is confirmed subject to the condition that the following are sent to Clinical Trials and Research Governance for review prior to submission, where required, to the Research Ethics Committee. Failure to do so may compromise insurance cover for the project.

- Any minor or substantial amendments
- Any extension to the trial end date
- Addition of any new research site or patient identification centre
- Any stoppage in study activities of any form that is anticipated or proves to be longer than one month and may result in the need to implement a formal temporary halt

In addition, annual progress reports, annual safety reports, the end of trial notification and final report must be copied to Clinical Trials and Research Governance.

Lastly, where they exist, University Core SOPs must be followed by default for all clinical trials sponsored by the University. Further information can be found here:
<https://researchsupport.admin.ox.ac.uk/ctrig/resources>

Any communications relating to Research Sponsorship should be directed to the undersigned.

Yours faithfully

Heather House

Head of Clinical Trials and Research Governance